Answers are grounded in this paper and cite their sources.
A retrospective analysis of two ECOG adult AML trials conducted from 1976 to 1983 was carried out focusing on long term disease-free survival. This report summarizes the data on 545 patients with a minimum follow up of 7 1/2 years. The complete remission rate was 57% with an estimated cure rate of 12%. Of several prognostic variables examined only FAB type M3 (promyelocytic leukemia) was statistically significant (estimated cure rate of 33% vs 9% for other FAB subtypes).
No takes yet. Share an insight, caveat, or question.
Bennett et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: